Lead Product(s): Cannabinol
Therapeutic Area: Genetic Disease Product Name: INM-755
Highest Development Status: Phase I Product Type: Small molecule
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 16, 2021
InMed intends to use the net proceeds from the offering for working capital purposes which also includes development of their INM-755 program.